Last reviewed 2026-04-22 · How we verify

Chemotherapy of Investigator's choice

Chemotherapy of Investigator's choice is a Small molecule drug developed by Guangzhou Gloria Biosciences Co., Ltd.. It is currently in Phase 3 development for Cancer (specific type and stage determined by investigator selection).

This is a phase 3 chemotherapy regimen selected by the investigator to treat cancer, with the specific mechanism dependent on the chosen chemotherapeutic agent(s).

This is a phase 3 chemotherapy regimen selected by the investigator to treat cancer, with the specific mechanism dependent on the chosen chemotherapeutic agent(s). Used for Cancer (specific type and stage determined by investigator selection).

At a glance

Mechanism of action

As an 'Investigator's choice' chemotherapy protocol, the exact mechanism is not predetermined but rather selected by the treating physician based on the patient's cancer type, stage, and prior treatment history. The chosen chemotherapy will typically work through DNA damage, microtubule disruption, or other cytotoxic mechanisms to inhibit cancer cell proliferation.

Approved indications

• Cancer (specific type and stage determined by investigator selection)

Common side effects

• Myelosuppression
• Nausea and vomiting
• Alopecia
• Mucositis
• Fatigue

Key clinical trials

• A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma (PHASE3)
• Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults (PHASE3)
• Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer (PHASE3)
• Fulzerasib Sequential Sintilimab Plus Platinum-Doublet Neoadjuvant Therapy for Resectable KRAS G12C-Mutant NSCLC (PHASE2)
• A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009) (PHASE3)
• Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations (PHASE3)
• A Phase III Study Evaluating YL201 Versus ICC in 2L ESCC (PHASE3)
• Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Chemotherapy of Investigator's choice CI brief — competitive landscape report
• Chemotherapy of Investigator's choice updates RSS · CI watch RSS
• Guangzhou Gloria Biosciences Co., Ltd. portfolio CI

Frequently asked questions about Chemotherapy of Investigator's choice

Related

• Manufacturer: Guangzhou Gloria Biosciences Co., Ltd. — full pipeline
• Therapeutic area: All drugs in Oncology
• Indication: Drugs for Cancer (specific type and stage determined by investigator selection)
• Compare: Chemotherapy of Investigator's choice vs similar drugs
• Pricing: Chemotherapy of Investigator's choice cost, discount & access